(Q53917235)

22 May 2018

title

Intravesical suramin in the prevention of transitional cell carcinoma. (English)

1 reference

22 May 2018

1 reference

S D Graham

1

1 reference

22 May 2018

P Napalkov

2

1 reference

22 May 2018

A Oladele

3

1 reference

22 May 2018

T E Keane

4

1 reference

22 May 2018

J A Petros

5

1 reference

22 May 2018

H S Clarke

6

1 reference

22 May 2018

V S Kassabian

7

1 reference

22 May 2018

D L Dillehay

8

1 reference

22 May 2018

language of work or name

English

0 references

publication date

1 January 1995

1 reference

22 May 2018

published in

Urology

1 reference

22 May 2018

volume

45

1 reference

22 May 2018

page(s)

59-63

1 reference

22 May 2018

issue

1

1 reference

22 May 2018

Suramin as an archetypical compound in the development of growth factor antagonists for inhibition of genitourinary tumors

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS0090-4295%2895%2996720-6

7 January 2021

Suramin, a novel antitumor compound.

1 reference

https://api.crossref.org/works/10.1016%2FS0090-4295%2895%2996720-6

7 January 2021

Suramin inhibits growth factor binding and proliferation by urothelial carcinoma cell cultures

1 reference

https://api.crossref.org/works/10.1016%2FS0090-4295%2895%2996720-6

7 January 2021

Rapid induction of bladder cancer in rats with N-methyl-N-nitrosourea. I. Histology

1 reference

https://api.crossref.org/works/10.1016%2FS0090-4295%2895%2996720-6

7 January 2021

The effects of basic fibroblast growth factor and suramin on cell motility and growth of rat prostate cancer cells

1 reference

https://api.crossref.org/works/10.1016%2FS0090-4295%2895%2996720-6

7 January 2021

The effect of suramin, tumor necrosis factor and interferon gamma on human prostate carcinoma

1 reference

https://api.crossref.org/works/10.1016%2FS0090-4295%2895%2996720-6

7 January 2021

Epidermal growth factor in the normal and neoplastic kidney and bladder

1 reference

https://api.crossref.org/works/10.1016%2FS0090-4295%2895%2996720-6

7 January 2021

Antiproliferative effects of suramin on androgen responsive tumour cells

1 reference

https://api.crossref.org/works/10.1016%2FS0090-4295%2895%2996720-6

7 January 2021

Suramin inhibition of growth factor receptor binding and mitogenicity in AKR-2B cells

1 reference

https://api.crossref.org/works/10.1016%2FS0090-4295%2895%2996720-6

7 January 2021

Epidermal growth factor receptor expression and suramin cytotoxicity in vitro

1 reference

https://api.crossref.org/works/10.1016%2FS0090-4295%2895%2996720-6

7 January 2021

Suramin, an Active Nonhormonal Cytotoxic Drug for Treatment of Prostate Cancer: Compelling Reasons for Testing in Patients With Hormone-Refractory Breast Cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0090-4295%2895%2996720-6

7 January 2021

A pilot study of suramin in the treatment of metastatic renal cell carcinoma

1 reference

https://api.crossref.org/works/10.1016%2FS0090-4295%2895%2996720-6

7 January 2021

Suramin-induced polyneuropathy

1 reference

https://api.crossref.org/works/10.1016%2FS0090-4295%2895%2996720-6

7 January 2021

Intravesical chemotherapy of superficial bladder cancer.

1 reference

https://api.crossref.org/works/10.1016%2FS0090-4295%2895%2996720-6

7 January 2021

Experimental intravesical therapy for superficial transitional cell carcinoma in a rat bladder tumor model

1 reference

https://api.crossref.org/works/10.1016%2FS0090-4295%2895%2996720-6

7 January 2021

10.1016/S0090-4295(95)96720-6

Identifiers

DOI

1 reference

22 May 2018

PubMed ID

7817482

1 reference

22 May 2018